These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 27884973)

  • 1. The emerging role of immune checkpoint inhibition in malignant lymphoma.
    Hude I; Sasse S; Engert A; Bröckelmann PJ
    Haematologica; 2017 Jan; 102(1):30-42. PubMed ID: 27884973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
    Xia Y; Medeiros LJ; Young KH
    Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas.
    Kasenda B; Kühnl A; Chau I
    Expert Rev Hematol; 2016; 9(2):123-35. PubMed ID: 26581237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint Inhibition in Hodgkin Lymphoma - a Review.
    Bröckelmann PJ; Engert A
    Oncol Res Treat; 2017; 40(11):654-660. PubMed ID: 29065424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitors in Organ Transplant Patients.
    Kittai AS; Oldham H; Cetnar J; Taylor M
    J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Therapy in Melanoma.
    Callahan MK
    Cancer J; 2016; 22(2):73-80. PubMed ID: 27111901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies.
    Ring KL; Pakish J; Jazaeri AA
    Cancer J; 2016; 22(2):101-7. PubMed ID: 27111905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
    Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
    Front Immunol; 2018; 9():1878. PubMed ID: 30158932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint inhibition in lymphoma.
    Shah GL; Moskowitz CH
    Clin Adv Hematol Oncol; 2018 Jan; 16(1):45-55. PubMed ID: 29741505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab in classical Hodgkin's lymphoma.
    Maly J; Alinari L
    Eur J Haematol; 2016 Sep; 97(3):219-27. PubMed ID: 27147112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Therapy and the Search for Predictive Biomarkers.
    Sharma P
    Cancer J; 2016; 22(2):68-72. PubMed ID: 27111900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Therapies in Prostate Cancer.
    Goswami S; Aparicio A; Subudhi SK
    Cancer J; 2016; 22(2):117-20. PubMed ID: 27111907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration.
    Campbell MT; Siefker-Radtke AO; Gao J
    Cancer J; 2016; 22(2):96-100. PubMed ID: 27111904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Immunotargets and Immunotherapies in Prostate Cancer.
    Montironi R; Santoni M; Sotte V; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Berardi R; Scarpelli M
    Curr Drug Targets; 2016; 17(7):777-82. PubMed ID: 26898309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.
    Dada R
    Ann Hematol; 2018 Apr; 97(4):555-561. PubMed ID: 29322203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.